Atossa Therapeutics
ATOS
12 hedge funds and large institutions have $1.08M invested in Atossa Therapeutics in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.
1,295% more capital inflows, than outflows
Capital inflows: $404K | Capital outflows: $28.9K
0.82% more ownership
Funds ownership: 2.44% → 3.27% (+0.82%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$162K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 3 |
Goldman Sachs
New York
|
+$68.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$29.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$24K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$4.92K |
ATOS Hedge Fund Activity: Q3 2014 in Review
12 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2014, worth a combined $1.08M — up 7.2% from $1.01M a quarter earlier.
Fund positioning in ATOS was balanced in Q3 2014: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 0 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $162K. The largest seller was Nomura Holdings, exiting entirely with an estimated $24K sold.
- 12 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $1.08M of Atossa Therapeutics stock for Q3 2014, up 7.2% quarter-over-quarter.
- 2 funds opened new Atossa Therapeutics positions in Q3 2014 and 2 closed out, a net change of 0 holders.
- The largest Atossa Therapeutics buyer in Q3 2014 was Virtu KCG Holdings, an estimated $162K added.
- The largest Atossa Therapeutics seller in Q3 2014 was Nomura Holdings, an estimated $24K sold.
Based on aggregated 13F filings for Q3 2014.